Abrahami et al. (2022) found no significant cancer risk associated with SGLT2i compared to GLP-1 receptor agonists or DPP-4 inhibitors in their international, multisite cohort study using the UK Clinical Practice Data Mart Database [71]. The gene discussed is DPP4; the disease is cancer.